

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
 Lassa fever	University of Oxford		IAVI		
 MERS	Uvax	IDT Barinthus/ University of Oxford			
 Nipah		PHV University of Oxford			
 Rift Valley fever	UC Davis Afrigen	Wageningen U.	University of Oxford and KEMRI – Wellcome Trust		
 Chikungunya				IVI/Bharat	Valneva
 COVID-19*					SK Bioscience Moderna Novavax University of Hong Kong Biological E Clover AZ/Oxford
 Broadly protective Betacoronavirus	MigVax IVI Bharat/U Syd/ExcellGene SK Bioscience Panacea/ THSTI VIDO CPI/CalTech NEC Intravacc				

(*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

		Preclinical		Phase I		Phase II		Phase IIb/III & III		Registration	
 Disease X	Akagera	Tiba bio									
	Chungbuk University	Gennova*		Lemonex	BioNTech						
	University of Queensland	Celestial									
	Moderna	Emervax									
	SK bio	HMRI									
	University of Oxford	Imperial									
	Curevac	Amplitude									
	Boost Biopharma	Nagasaki University									
	Centivax	VitriVax									
	ACM Bio	Abera Bioscience									
 Broadly protective Filovirus vaccines	Adaptvac										

(*) Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.

All .

	DISEASE	DEVELOPER	PHASE	PLATFORM	CEPI FUNDING (IN USD)
	Lassa fever	University of Oxford	Preclinical	Viral Vector	Up to \$19 million‡
		IAVI	Phase 2	Viral Vector	Up to \$64.4 million
	MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to \$47 million‡
		IDT	Phase I	Viral vector	Up to \$36 million
	Nipah	Uvax bio	Preclinical	Nanoparticle	Up to \$2.6 million
		University of Oxford	Phase I	Viral Vector	Up to \$19 million‡
	Rift Valley fever	PHV	Phase I	Viral vector	Up to \$43.6 million
		UC Davis	Preclinical	Live attenuated	Up to \$40 million
		Wageningen University	Phase I	Live attenuated	Up to \$38.4 million
		University of Oxford and KEMRI-Wellcome Trust	Phase II	Viral Vector	Up to \$3.7 million
	Chikungunya	Afrigen	Preclinical	RNA	Up to \$6.2 million
		IVI/Bharat	Phase IIb/III	Inactivated	Up to \$14.1 million
	COVID-19	Valneva	Registration	Live attenuated	Up to \$65.9 million
		SK Bioscience	Registration	Protein based	Up to \$210 million
		Biological E	Registration	Protein based	Up to \$14 million
		Moderna	Registration	Protein based	Up to \$1 million
		Clover	Registration	Protein based	Up to \$397.4 million
		AZ/University of Oxford	Registration	Viral vector	Up to \$384 million
		Novavax	Registration	Protein based	Up to \$399 million

(‡) Includes Lassa, MERS and Nipah funding

(**) Includes COVID-19 variant and BPBC funding. Project funding complete.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

(##) Includes \$13.38 million for funding a Nipah candidate and \$3.6 for funding for a Rabies candidate/platform optimisation.

 Broadly protective Beta-coronavirus	MigVax	Preclinical	Protein based	Up to \$4.3 million
	BioNet	Preclinical	RNA	Up to \$16.9 million
	VIDO	Preclinical	Protein based	Up to \$22 million
	Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to \$19.9 million
	CPI/Caltech	Preclinical	Protein based	Up to \$30 million
	NEC	Preclinical	RNA	Up to \$4.8 million
	SK Bioscience	Preclinical	Protein based	Up to \$50 million
	Panacea/THSTI	Preclinical	Protein based	Up to \$12.5 million
	Intravacc	Preclinical	Protein based	Up to \$4.8 million
 Disease X	Akagera	Preclinical	RNA	Up to \$1.5 million
	ACM Bio	Preclinical	RNA	Up to \$2.9 million
	Amplitude	Preclinical	RNA	Up to \$1 million
	BioNTech	Phase I/II	RNA	Up to \$90 million
	Boost Biopharma	Preclinical	Protein based	Up to \$5 million
	Celestial	Preclinical	RNA	Up to \$0.7 million
	Centivax	Preclinical	RNA	Up to \$5.0 million
	Chungbuk National University	Preclinical	RNA	Up to \$0.9 million
	Curevac	Preclinical	RNA	Up to \$34 million
	Emervax	Preclinical	RNA	Up to \$2.2 million
	Gennova	Preclinical	RNA	Up to \$16.98 million##
	HMRI	Preclinical	RNA	Up to \$3.8 million
	Imperial College London	Preclinical	RNA	Up to \$8.4 million
	Lemonex	Phase I	RNA	Up to \$4.9 million
	Moderna	Preclinical	RNA	Not yet at a stage where CEPI provides funding to Moderna.
	Nagasaki University	Preclinical	RNA	Up to \$5 million
	University of Oxford	Preclinical	Viral Vector	Up to \$80 million
	University of Queensland	Preclinical	Protein based	Up to \$10.6 million
	SK Bioscience	Preclinical	RNA	Up to \$40 million
	Tiba Bio	Preclinical	RNA	Up to \$2 million
	VitriVax	Preclinical	ALTA®	Up to \$5 million
 Broadly protective Filovirus vaccines	AdaptVac	Preclinical	Virus-like particle	Up to \$12.4 million